Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Economics & Value
Economics & Value
Articles about real-world healthcare utilization and costs on Value-Based Cancer Care.
Filter by Topic
Accountable Care Organization
Community Oncology
Comparative Effectiveness
Comparative Effectiveness Research
Economics of Cancer Care
Health Economics
Oncology Benefit Edition
Payer-Provider
Pricing
Reimbursement
Value-Based Care
Dabrafenib-Trametinib Combination Projected to Improve Survival at Increased Cost versus Other First-Line Therapies in Metastatic Melanoma
By
Alice Goodman
Economics & Value
,
Economics of Cancer Care
June 2014, Vol 5, No 5
Tampa, FL—Combining dabrafenib (Tafinlar) with trametinib (Mekinist) as upfront treatment for patients diagnosed with
BRAF V600
mutation–positive metastatic melanoma should lead to improved survival, but it increases the direct costs of treatment compared with other first-line therapies.
Read Article
Insurance Coverage for Genetic Testing and Personalized Medicine: Which Way Is the Wind Blowing?
By
Alice Goodman
Economics & Value
,
Economics of Cancer Care
June 2014, Vol 5, No 5
Tampa, FL—Genetic testing and targeted medicines, the key players in personalized medicine, are seen as the waves of the future for managing patients with cancer, but getting there remains a challenge when it comes to insurance coverage for these expensive tests and therapies.
Read Article
Aetna’s Model of Value-Based, Financially Viable Accountable Care Improves Health Outcomes
By
Rosemary Frei, MSc
Economics & Value
,
Economics of Cancer Care
June 2014, Vol 5, No 5
Charles Kennedy, MD, Chief Executive Officer of Aetna’s Accountable Care Solutions, is responsible for leading Aetna’s accountable care partnerships with healthcare providers. Dr Kennedy also serves as the health insurance industry representative on the Health IT Policy Committee, a federal advisory committee that makes recommendations to the National Coordinator for Health IT on a policy framework for the development and adoption of a nationwide health information infrastructure.
Read Article
Frequent Mammography Screening for Breast Cancer Adds Billions to Cost
By
Rosemary Frei, MSc
Economics & Value
,
Economics of Cancer Care
May 2014, Vol 5, No 4
The total annual cost of mammography screening for women aged 40 to 85 years in the United States is estimated to be $7.8 billion, according to a new analysis (O’Donoghue C, et al.
Ann Intern Med
. 2014;160:145-153). That is $4.3 billion more than the cost would be if mammography intervals were lowered to fall in line with the recommendations of the US Preventive Services Task Force (USPSTF), the study researchers calculated.
Read Article
Value Propositions
Economics & Value
,
Value Peer-spectives
May 2014, Vol 5, No 4
Value Propositions for May 2014.
Read Article
Challenges Facing US Cancer Care in 2014: ASCO’s First Annual Report to the Nation
By
Eileen Koutnik-Fotopoulos
Economics & Value
,
Economics of Cancer Care
May 2014, Vol 5, No 4
Advances in cancer treatment, from detection and diagnosis to drugs, surgical techniques, and new imaging capabilities, have collectively enabled many patients to live longer, healthier lives with or after cancer. However, a new landmark report, “The State of Cancer Care in America, 2014: A Report by the American Society of Clinical Oncology” (ASCO), identifies the many challenges that will impact the future delivery of cancer care (ASCO.
J Oncol Pract
. 2014;10:119-143). These challenges include an increasing demand for care, predicted workforce shortages, rapidly rising costs, imbalances in access to care, and an unstable practice environment.
Read Article
Promise of Personalized Care Hinges on Reimbursement Reform
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
April 2014, Vol 5, No 3
The promise of big data–driven personalized healthcare mandates reform of the oncology reimbursement system, suggested Jeffery C. Ward, MD, Medical Oncologist, Swedish Cancer Institute, Edmonds, WA, in a recent commentary.
Read Article
Implications of the ACA for Cancer Care
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
April 2014, Vol 5, No 3
Hollywood, FL—The Affordable Care Act (ACA) is in its infancy, but it is already changing oncology practice, said panelists at the 2014 National Comprehensive Cancer Network (NCCN) Conference roundtable discussion. The consequences of the ACA include the changing composition of oncology patients, the risk pool of the exchanges, new payment and reimbursement models, acquisition fever, and oncology workforce demands, the panelists said.
Read Article
ACA Heralds Modest Increase in Healthcare Utilization for Testicular Seminoma
By
Alice Goodman
Economics & Value
,
Economics of Cancer Care
March 2014, Vol 5, No 2
San Francisco, CA—Concerns that healthcare utilization will increase dramatically once more patients are insured under the Affordable Care Act (ACA) may be overblown, based on results of a large study of Medicaid and underinsured patients with seminoma, the most common type of testicular cancer.
Read Article
Switching from Intravenous to Subcutaneous Rituximab Saves Staff Time and Money
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
March 2014, Vol 5, No 2
New Orleans, LA—The efficiency of rituximab (Rituxan) and the associated cost can be improved by switching from intravenous (IV) to subcutaneous (SC) administration. Such a switch led to a substantial reduction in patient chair time and in active healthcare professional time, said Christof Wiesner, PhD, MPH, of the Market Access Department, Genentech, San Francisco, CA, at the ASH 2013 meeting.
Read Article
Page 11 of 18
6
7
8
9
10
11
12
13
14
15
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma